Positive results from phase I clinical trial of SMT D002 for the treatment of Seborrhoea
SMT D002 suppresses sebum levels by 90% in repeat-dose trial
The study was conducted in 18 healthy volunteers and examined the effect of repeat oral doses of SMT D002 over a four-day period. The key findings of the Phase I clinical trial are:
- Statistically significant levels of sebum suppression (primary endpoint) of 90% when compared to the placebo group (p=0.04)
- SMT D002 proved to be safe with no serious or unexpected adverse side-effects reported
- Sebum levels measured over six hours following treatment using a Sebumeter, an industry accepted method
- Results from trial support a previous positive Phase I single-dose study conducted in nine volunteers
The results of this trial confirm the potential of SMT D002 as a new therapeutic agent for the treatment of seborrhoea in acne patients. Summit plans to develop a topical formulation of SMT D002 to further evaluate its efficacy in the treatment of acne and the Company is actively seeking a commercial partner to advance this candidate from the clinic through to the market.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.